Equity (Tables)

12 Months Ended

Dec. 31, 2016

Stockholders' Equity Note [Abstract]

Schedule of Warrants and Share Options

	Year ended December 31
	2016					2015
	Number of warrants and options			Weighted average exercise price		Number of warrants and options			Weighted average exercise price
Outstanding - beginning of period		28,548		$	752.5		21,463		$	1002.5
Granted		328,698			4.57		8,599			132.5
Forfeited		(20,861	)		689.47		(1,514	)		767
Exercised		(153	)		-
Outstanding -end of period		336,232		$	25.48		28,548		$	752.5
Exercisable at the end of the period		51,275		$	145.35		13,792		$	1,159.25

	Year ended December 31
	2016					2015
	Number of warrants and options			Weighted average exercise price		Number of warrants and options			Weighted average exercise price
Outstanding - beginning of period		5,372		$	1,134		5,597		$	1,120
Granted		-			-		-			-
Forfeited		(3,722	)		1,278.55		(225	)		766.75
Exercised		(147	)		-
Outstanding - end of period		1,503		$	890.42		5,372		$	1,134.25
Exercisable at the end of the period		1,485		$	886.28		5,356		$	1,134

Schedule of Information About Restricted Shares to Employees

	Year ended December 31
	2016			2015
	Number of restricted shares
Outstanding - beginning of period		5,889			4,103
Granted		129,825			7,866
Forfeited		(1,266	)		(406	)
Vested		(3,999	)		(5,674	)
Outstanding - end of period		130,449			5,889

Schedule of Warrants and Options Outstanding and Exercisable

	Outstanding as of December 31, 2016
Exercise price	Warrants and options outstanding		Weighted average remaining contractual life (years)		Warrants and options exercisable
$0-$1.86		45,823		9.76		382
$3.04-$3.25		143,400		4.68		-
$4.75-$12.5		139,857		9.51		43,932
$42.5-$207.5		3,405		7.43		3,280
$557.5-$2,100		5,250		3.89		5,165
		337,735		7.39		52,760

Schedule of Assumptions Used in Fair Value of Options Granted to Employees

	Year ended December 31
	2016			2015
Expected life	5-6.5 years			5-6.5 years
Risk-free interest rates		1.01%-2.06%			1.41%-1.71%
Volatility		85.8%-91.03%			62.68%-71.12%
Dividend yield		0	%		0	%

Schedule of Allocation of Total Share-based Compensation Expense

	Year ended December 31
	2016			2015
	($ in thousands)
Cost of revenues	$	1		$	8
Research and development		182			716
Sales and marketing		(85	)		179
General and administrative		880			2,145
Restructuring and impairment		-			59
	$	978		$	3,107